116 related articles for article (PubMed ID: 7104178)
1. Predictive indices for chlorpromazine therapy in schizophrenics.
Dixon PA; Oforah E; Makanjuola R
Br J Clin Pharmacol; 1982 Aug; 14(2):273-7. PubMed ID: 7104178
[TBL] [Abstract][Full Text] [Related]
2. Prediction of response to chlorpromazine treatment in schizophrenics.
Sakurai Y; Nakahara T; Takahashi R
Psychopharmacologia; 1975 Oct; 44(2):195-203. PubMed ID: 1105634
[TBL] [Abstract][Full Text] [Related]
3. Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial.
Lal S; Thavundayil JX; Nair NP; Annable L; Ng Ying Kin NM; Gabriel A; Schwartz G
J Psychiatry Neurosci; 2006 Jul; 31(4):271-9. PubMed ID: 16862245
[TBL] [Abstract][Full Text] [Related]
4. Total and free plasma neuroleptic levels in schizophrenic patients.
Tang SW; Glaister J; Davidson L; Toth R; Jeffries JJ; Seeman P
Psychiatry Res; 1984 Dec; 13(4):285-93. PubMed ID: 6596586
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Electroconvulsive Therapy and Associated Cognitive Change in Schizophrenia: A Naturalistic, Comparative Study of Treating Schizophrenia With Electroconvulsive Therapy.
Tor PC; Ying J; Ho NF; Wang M; Martin D; Ang CP; Tan C; Yap LS; Lu VJM; Simpson B; Mok YM; Loo C
J ECT; 2017 Dec; 33(4):272-277. PubMed ID: 28640170
[TBL] [Abstract][Full Text] [Related]
6. Effects of trihexyphenidyl on plasma chlorpromazine in young schizophrenics.
Rockland L; Cooper T; Schwartz F; Weber D; Sullivan T
Can J Psychiatry; 1990 Oct; 35(7):604-7. PubMed ID: 2268840
[TBL] [Abstract][Full Text] [Related]
7. Promazine. A major plasma metabolite of chlorpromazine in a population of chronic schizophrenics.
Sgaragli G; Ninci R; Della Corte L; Valoti M; Nardini M; Andreoli V; Moneti G
Drug Metab Dispos; 1986; 14(2):263-6. PubMed ID: 2870904
[TBL] [Abstract][Full Text] [Related]
8. Prediction of drug responses in schizophrenia: a method using a test dose of chlorpromazine.
Minami H; Nakahara T; Miyahara A; Nakane Y
Psychiatry Clin Neurosci; 1997 Aug; 51(4):217-22. PubMed ID: 9316167
[TBL] [Abstract][Full Text] [Related]
9. Prediction of response to and actual outcome of chlorpromazine treatment in schizophrenic patients.
Sakurai Y; Takahashi R; Nakahara T; Ikenaga H
Arch Gen Psychiatry; 1980 Sep; 37(9):1057-62. PubMed ID: 7416905
[TBL] [Abstract][Full Text] [Related]
10. Quetiapine : A Review of its Use in Schizophrenia.
Gunasekara NS; Spencer CM
CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
[TBL] [Abstract][Full Text] [Related]
11. Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine.
Wode-Helgodt B; Borg S; Fyrö B; Sedvall G
Acta Psychiatr Scand; 1978 Aug; 58(2):149-73. PubMed ID: 358755
[TBL] [Abstract][Full Text] [Related]
12. Integrated EEG. variability: drug effects in acute schizophrenics.
Marjerrison G; Keogh RP
Can Psychiatr Assoc J; 1969 Aug; 14(4):403-5. PubMed ID: 4897659
[No Abstract] [Full Text] [Related]
13. Correlation between plasma chlorpromazine and its metabolites and clinical ratings in patients with acute relapse of schizophrenic and paranoid psychosis.
Phillipson OT; McKeown JM; Baker J; Healey AF
Br J Psychiatry; 1977 Aug; 131():172-84. PubMed ID: 912219
[TBL] [Abstract][Full Text] [Related]
14. Dehalogenation and N-dealkylation of chlorpromazine as revealed by plasma concentrations of metabolites in a population of chronically medicated schizophrenics.
Valoti M; Palmi M; Della Corte L; Nardini M; Corti P; Sgaragli GP
Methods Find Exp Clin Pharmacol; 1992; 14(6):445-50. PubMed ID: 1469953
[TBL] [Abstract][Full Text] [Related]
15. A longitudinal therapeutic comparison between two prototypic neuroleptics (haloperidol and chlorpromazine) in matched groups of schizophrenics. Nontherapeutic interactions with trihexyphenidyl. Theoretical implications for potency differences.
Singh MM; Kay SR
Psychopharmacologia; 1975 Aug; 43(2):115-21. PubMed ID: 1103206
[TBL] [Abstract][Full Text] [Related]
16. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia.
Reschke RW
Dis Nerv Syst; 1974 Mar; 35(3):112-5. PubMed ID: 17894080
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the anti-dopamine D₂ and anti-serotonin 5-HT(2A) activities of chlorpromazine, bromperidol, haloperidol and second-generation antipsychotics parent compounds and metabolites thereof.
Suzuki H; Gen K; Inoue Y
J Psychopharmacol; 2013 Apr; 27(4):396-400. PubMed ID: 23427194
[TBL] [Abstract][Full Text] [Related]
18. The HLA system and the clinical response to treatment with chlorpromazine.
Smeraldi E; Bellodi L; Sacchetti E; Cazzullo CL
Br J Psychiatry; 1976 Nov; 129():486-9. PubMed ID: 825177
[TBL] [Abstract][Full Text] [Related]
19. A double blind controlled study of ECT vs chlorpromazine in schizophrenia.
Bagadia VN; Abhyankar RR; Doshi J; Pradhan PV; Shah LP
J Assoc Physicians India; 1983 Oct; 31(10):637-40. PubMed ID: 6671932
[No Abstract] [Full Text] [Related]
20. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
Conley RR; Tamminga CA; Bartko JJ; Richardson C; Peszke M; Lingle J; Hegerty J; Love R; Gounaris C; Zaremba S
Am J Psychiatry; 1998 Jul; 155(7):914-20. PubMed ID: 9659857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
